Objective To determine how mental disorders and psychopharmacological treatments before and during COVID‐19 hospital admissions are related to mortality. Methods Subjects included in the study were all adult patients with a diagnosis of COVID‐19, confirmed clinically and by PCR, who were admitted to a tertiary university hospital in Badalona (Spain) between March 1 and November 17, 2020. Data were extracted anonymously from computerized clinical records. Results 2,150 subjects were included, 57% males, mean age 61 years. History of mental disorders was registered in 957 (45%). Throughout admission, de novo diagnosis of mood or anxiety, stress, or adjustment disorder was made in 12% of patients without previous history. Delirium was diagnosed in 10% of cases. 1011 patients (47%) received a psychotropic prescription during admission (36% benzodiazepines, 22% antidepressants, and 21% antipsychotics). Mortality rate was 17%. Delirium during admission and history of mood disorder were independently associated with higher mortality risk (hazard ratios, 1.39 and 1.52 respectively), while previous year's treatments with anxiolytics/hypnotics and antidepressants were independently associated with lower mortality risk (hazard ratios, 0.47 and 0.43, respectively). Conclusion Mental symptoms are very common in patients hospitalized for COVID‐19 infection. Detecting, diagnosing, and treating them is key to determining the prognosis of the disease and functional recovery.

Objectives The current study aimed at evaluating the reliability, convergent and divergent validity, and factor structure of the Spanish Launay–Slade Hallucinations Scale‐Extended version (LSHS‐E) in people with mental disorders and healthy controls. Methods Four hundred and twenty‐two individuals completed the Spanish LSHS‐E and the Spanish Community Assessment of Psychic Experiences. The convergent and divergent validity of the LSHS‐E was assessed with the three dimensions of the Community Assessment of Psychic Experiences (positive, negative, and depressive dimensions) in healthy controls and people with a mental disorder. Factor structure of the LSHS‐E was assessed using confirmatory factor analysis and measurement invariance. Results The LSHS‐E had a good reliability in healthy controls and people with a mental disorder (Cronbach's = 0.83 and 0.91, respectively). The LSHS‐E was more strongly associated with positive psychotic‐like experiences than with depressive and negative symptoms. Four factors were found: (a) “intrusive thoughts”; (b) “vivid daydreams”; (c) “multisensory hallucination‐like experiences”; and (d) “auditory–visual hallucination‐like experiences” that were invariant between the group of healthy controls and people with a mental disorder. Conclusion The Spanish version of the LSHS‐E possesses adequate psychometric properties, and the confirmatory factor analysis findings provide further support for the multidimensionality of proneness to hallucination in clinical and nonclinical samples.